58777-65-4

Usage

Uses

Used in Pharmaceutical Industry:
4-BROMO-2-THIOPHENECARBONYL CHLORIDE is used as a key intermediate for the synthesis of a wide range of drugs and pharmaceutical products. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Production:
In the agrochemical industry, 4-BROMO-2-THIOPHENECARBONYL CHLORIDE is utilized as a precursor in the synthesis of various agrochemicals, contributing to the development of effective pest control agents and other agricultural products.
Used in Specialty Chemicals:
4-BROMO-2-THIOPHENECARBONYL CHLORIDE is employed as a versatile intermediate in the production of specialty chemicals, which are used in various industries such as plastics, coatings, and textiles.
Used in Organic Synthesis:
As a valuable reagent in organic chemistry, 4-BROMO-2-THIOPHENECARBONYL CHLORIDE is used for the formation of carbon-carbon and carbon-heteroatom bonds, facilitating the synthesis of complex organic molecules and biologically active compounds.
Used in Drug Development:
4-BROMO-2-THIOPHENECARBONYL CHLORIDE is utilized in the preparation of biologically active compounds, playing a significant role in the discovery and development of innovative drugs with potential therapeutic benefits.

InChI:InChI=1/C5H2BrClOS/c6-3-1-4(5(7)8)9-2-3/h1-2H

Upstream product

• 16694-18-1 4-bromo-thiophene-2-carboxylic acid 
• 18791-75-8 4-Bromothiophen-2-aldehyde 

Downstream Products

• 98215-49-7 4-Bromo-thiophene-2-carboxylic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-amide 
• 66938-33-8 (4-bromo-2-thienyl)(4-methoxyphenyl)methanone 
• 62224-16-2 4-bromothiophene-2-carboxylic acid methyl ester 
• 111690-61-0 (3-bromo-2-thienyl)(4-methoxyphenyl)methanone ethylene ketal 
• 111690-62-1 (4-trifluoroacetyl-2-thienyl)(4-methoxyphenyl)methanone hydrate 
• 111690-68-7 (3,4-Diamino-phenyl)-[4-(3-trifluoromethyl-3H-diazirin-3-yl)-thiophen-2-yl]-methanone 
• 111690-63-2 (4-trifluoroacetyl-2-thienyl)(3-nitro-4-methoxyphenyl)methanone 
• 111690-67-6 <4-(1-azi-2,2,2-trifluoroethyl)-2-thienyl>(3-nitro-4-aminophenyl)methanone 
• 111690-72-3 (4-Methoxy-3-nitro-phenyl)-[4-(3-trifluoromethyl-diaziridin-3-yl)-thiophen-2-yl]-methanone 
• 111690-66-5 <4-(1-azi-2,2,2-trifluoroethyl)-2-thienyl>(3-nitro-4-methoxyphenyl)methanone 
• 111690-64-3 1-<2-(3-nitro-4-methoxybenzoyl)-4-thienyl>-2,2,2-trifluoroethanone oxime 
• 111690-69-8 2,2,2-Trifluoro-1-{5-[2-(4-methoxy-phenyl)-[1,3]dioxolan-2-yl]-thiophen-3-yl}-1-piperidin-1-yl-ethanol 
• 111690-70-1 1-<2-(3-nitro-4-methoxybenzoyl)-4-thienyl>-2,2,2-trifluoroethanone O-<(4-methylphenyl)sulfonyl>oxime 
• 660399-71-3 ethyl 4-{[(4-bromothien-2-yl)carboxamido]methyl}benzoate 

Relevant academic research and scientific papers

N-Aromatic-Substituted Indazole Derivatives as Brain-Penetrant and Orally Bioavailable JNK3 Inhibitors

An indazole/aza-indazole scaffold was developed as a novel chemotype for JNK3 inhibition. Extensive structure activity relationship (SAR) studies utilizing various in vitro and in vivo assays led to potent and highly selective JNK3 inhibitors with good oral bioavailability and high brain penetration. One lead compound, 29, was a potent and selective JNK3 inhibitor (IC50 = 0.005 μM) that had significant inhibition (>80% at 1 μM) to only JNK3 and JNK2 in a panel profiling of 374 wild-type kinases, had high potency in functional cell-based assays, had high stability in the human liver microsome (t1/2 = 92 min), and was orally bioavailable and brain penetrant (brain/plasma ratio: 56%). The cocrystal structure of 29 in human JNK3 at a 2.1 ? resolution showed that indazole or aza-indazole-based JNK3 inhibitors demonstrated a type I kinase inhibition/binding.

Enantioselective Synthesis of Five-Membered-Ring Atropisomers with a Chiral Rh(III) Complex

Axially chiral atropisomeric compounds are widely applied in asymmetric catalysis and medicinal chemistry, and efficient methods for their synthesis are in high demand. This applies in particular to atropisomers derived from five-membered aromatic rings because their lower barrier for rotation among the biaryl axis limits their asymmetric synthesis. We report here an enantioselective C-H functionalization method using our chiral RhJasCp complex for the synthesis of the biaryl atropisomer types that can be accessed from three different five-membered-ring heterocycles.

Novel, potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities

17β-Hydroxysteroid dehydrogenase type 2 (17β-HSD2) is responsible for the oxidation of the highly active estradiol (E2) and testosterone (T) into the less potent estrone (E1) and Δ4-androstene-3,17-dione (Δ4-AD), respectively. As 17β-HSD2 is present in bones and as estradiol and testosterone are able to induce bone formation and repress bone resorption, inhibition of this enzyme could be a new promising approach for the treatment of osteoporosis. Herein, we describe the design, the synthesis and the biological evaluation of 24 new 17β-HSD2 inhibitors in the 5-substituted thiophene-2-carboxamide class. Structure-activity and structure-selectivity relationships have been explored by variation of the sulfur atom position in the central core, exchange of the thiophene by a thiazole, substitution of the amide group with a larger moiety, exchange of the N-methylamide group with bioisosteres like N-methylsulfonamide, N-methylthioamide and ketone, and substitutions at positions 2 and 3 of the thiophene core with alkyl and phenyl groups leading to 2,3,5-trisubstituted thiophene derivatives. The compounds were evaluated on human and mouse enzymes. From this study, a novel highly potent and selective compound in both human and mouse 17β-HSD2 enzymes was identified, compound 21 (IC 50(h17β-HSD2) = 235 nM, selectivity factor toward h17β-HSD1 = 95, IC50 (m17β-HSD2) = 54 nM). This new compound 21 could be used for an in vivo proof of principle to demonstrate the true therapeutic efficacy of 17β-HSD2 inhibitors in osteoporosis. New structural insights into the active sites of the human and mouse enzymes were gained.

Selective nitrile inhibitors to modulate the proteolytic synergism of cathepsins S and F

A series of dipeptide nitriles with different P3 substituents was designed to explore the S3 binding pocket of cathepsin S. Racemic 7-16 and the enantiopure derivative (R)-22 proved to be potent inhibitors of human cathepsin S and exhibited notable selectivity over human cathepsins L, K, and B. Inhibition of cathepsin F, the functional synergist of cathepsin S, was not observed. The azadipeptide analogue of 22, compound 26, was highly potent but nonselective.

Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease

Novel multifunctional compounds have been designed, synthesized, and evaluated as potential drugs for the treatment of Alzheimer's disease (AD). With an L-glutamic moiety as a suitable biocompatible linker, three pharmacophoric groups were joined: (1) anN

INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS

Compounds of Formula (I), wherein n is 1 or 2, and R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein, their preparation, pharmaceutical compositions, and methods of use are disclosed.

N-Glycosyl-thiophene-2-carboxamides: synthesis, structure and effects on the growth of diverse cell types

A range of N-glycosyl-thiophene-2-carboxamides, including a 6H-thieno[2,3-c]pyridin-7-one and a bivalent compound, have been synthesised and assayed for their effects on DNA synthesis in bovine aortic endothelial cells or on the growth of synoviocytes. Per-O-acetylated analogues of the glycoconjugates were significantly more effective inhibitors when compared to their corresponding non-acetylated analogues, indicating that the lower potency observed for hydroxylated derivatives is due to less efficient transport of these compounds across the cell membrane. Thiophene-2-carboxamide was inactive as an inhibitor of bFGF induced proliferation, confirming the requirement of the carbohydrate residue for the observed biological properties. Glucose, mannose, galactose and 2-amino-2-deoxy-glucose analogues were active as were a variety of substituted thiophene derivatives; the 6H-thieno[2,3-c]pyridin-7-one conjugate was inactive. Conformational analysis of the title compounds was investigated. X-ray crystal structural analysis of four N-glucosyl-thiophene-2-carboxamides showed that the pyranose rings adopted the expected 4C1 conformations and that Z-anti structures were predominant (H1-C1-N-H anomeric torsion angle varied from -168.2° to -175.0°) and that the carbonyl oxygen and sulfur of the thiophene adopted an s-cis conformation in three of the isomers. In a crystal structure of a 3-alkynyl derivative, the hydrogen atom of the NH group was directed toward the acetylene group. The distance between the hydrogen atom and acetylene carbons and angles between nitrogen, hydrogen and carbon atoms were consistent with hydrogen bonding and this was supported by IR and NMR spectroscopic studies. The geometries of thiophene-2-carboxamides were explored by density functional theory (DFT) and Moller-Plesset (MP2) calculations and the s-cis conformer of thiophene-2-carboxamide was found to be more stable than its s-trans isomer by 0.83 kcal mol-1. The s-cis conformer of 3-ethynyl-thiophene-2-carboxamide was 5.32 kcal mol-1 more stable than the s-trans isomer. The larger stabilisation for the s-cis conformer in the 3-alkynyl derivatives is explained to be due to a moderate hydrogen bonding interaction between the alkyne and NH group.

Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors

A new class of MMP-12 inhibitors was discovered and optimized using structure-based drug design methods. Modeling studies using a known MMP-12 crystal structure identified a new interaction mode for these new MMP-12 inhibitors. Further optimization resulted in the discovery of a compound displaying nanomolar activity against MMP-12 and which was co-crystallized with MMP-12.

Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them

A compound of formula (I) selected from: wherein: X represents oxygen or sulphur, Y represents oxygen, —NH— or —N(C1-C6)alkyl-, Ra represents hydrogen, halogen, (C1-C3)alkyl, hydroxyl or (C1-C3)alkoxy, Rb represents hydrogen, halogen or (C1-C3)alkyl, A represents phenyl, pyridyl, (C5-C6)cycloalkyl or (C5-C6)cycloalkenyl, R1 and R2 each represent a group selected from hydrogen, halogen, cyano, nitro, haloalkyl, haloalkoxy, alkyl, alkenyl, alkynyl, —OR4, —NR4R5, —S(O)nR4, —C(O)R4, —CO2R4, —O—C(O)R4, —C(O)NR4R5, —NR5—C(O)R4, —NR5—SO2R4, -T-CN, -T-OR4, -T-OCF3, -T- NR4R5, -T-S(O)nR4, -T-C(O)R4, -T-CO2R4, -T-O—C(O)R4, -T-C(O)NR4R5, -T-NR4—C(O)R5, -T-NR4—SO2R5, —R6 and -T-R6 in which n, T, R4, R5 and R6 are as defined in the description, R3 represents an —R7 or —U—R11 group in which R7 represents hydrogen, alkyl, aryl, cycloalkyl or heterocycle, U represents a linear or branched alkylene chain and R11 is defined in the description, their optical isomers or their addition salts with a pharmaceutically acceptable acid or base, and their use as inhibitor of metalloproteinase and more specifically of metalloproteinase-12.